Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B

Thrombosis Research

Volumn 131, Issue SUPPL.2, 2013, Pages

  Martinowitz, Uri ^a   Lubetsky, Aaron ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Albumin fusion protein; Factor IX; Hemophilia B; Pharmacokinetics; PROLONG 9FP; Recombinant albumin

Indexed keywords

ALBUMIN; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 9 ALBUMIN FUSION PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLERGIC REACTION; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEMOPHILIA B; HUMAN; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ALBUMINS; FACTOR IX; HEMOPHILIA B; HUMANS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 84875539641     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(13)70152-X     Document Type: Conference Paper

References (12)

1. HJ Metzner, T Weimer, U Kronthaler et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX Thromb Haemost 102 2009 634 644
2. IM Nilsson, E Berntorp, T Löfqvist, H Pettersson Twenty-five years' experience of prophylactic treatment in severe haemophilia A or B J Intern Med 232 1992 25 32
3. SC Darby, S Wan Kan, RJ Spooner et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV Blood 110 2007 815 825 (Pubitemid 47267416)
4. W Royal, W Schramm, E Berntorp et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients Haemophilia 8 2002 44 50 (Pubitemid 34257918)
5. GC White 2nd, A Beebe, B Nielsen Recombinant factor IX Thromb Haemost 78 1997 261 265 (Pubitemid 27289251)
6. BM Ewenstein, JH Joist, AD Shapiro et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B Transfusion 42 2002 190 197
7. S Björkman, AD Shapiro, E Berntorp Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis Haemophilia 7 2001 133 139 (Pubitemid 32243794)
8. HJ Metzner, T Weimer, S Schulte Half-life extension by fusion to recombinant albumin R Kontermann Therapeutic proteins. Strategies to modulate their plasma half-life 2012 Wiley-VCH Verlag & Co. Weinheim 223 247
9. MW Nolte, TC Nichols, J Mueller-Cohrs et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs J Thromb Haemost 10 2012 1591 1599
10. A Lubetsky, T Lissitchkov, G Yotov et al. Safety and pharmacokinetic results of a phase I/II clinical trial of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated patients with hemophilia B (PROLONG-9FP) Haemophilia 18 Suppl 3 2012 24 [Abstract PO-WE-055].
11. E Santagostino, C Negrier, R Klamroth et al. Results of a phase I international clinical trial of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in patients with hemophilia B (PROLONG-9FP) Hämostaseologie 32 2012 A12 [Abstract ED09-7].
12. E Santagostino, C Negrier, R Klamroth et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients Blood 120 2012 2405 2411